PTC Therapeutics, Inc. (PTCT)
割安ファンダメンタル
57
株価
$64.63
時価総額
$5.41B
パート1 · 企業の価値
概要
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$1.01B
直近12か月（2026/6/30まで）
純利益
$-38M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$702M
自己資本合計
$-205M
負債合計
$3.10B
流動比率
3.39
利払い倍率
-
負債/EBITDA
0.77
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$152.32
現在株価
$64.63
安全マージン
+57.6%
適正価値レンジ
$99.01 - $205.63
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
8.33
ROE
-332.5%
P/B レシオ
-
P/FCF
7.70
粗利益率
-
ROIC
4.0%
収益性レーダー
価値創造（経済的モート）
ROIC
4.0%
WACC
7.1%
ROIC − WACC
-3.1 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（10）
- EPS shows upward trend
- Price CAGR 19.04%
- P/FCF 7.70
- Operating Margin 12.5%
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Revenue Growth 5Y 135.4%
- Analyst Consensus 81% Buy
- Piotroski F-Score 6/9
不合格（9）
- EPS CAGR 3.91%
- ROIC 4.0%
- Positive Free Cash Flow
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -351.9%
- Earnings Surprise avg -1034.0%
- Share Dilution 14.2%
- Net Margin Trend -3.8% vs 35.6%
データなし（9）
- Gross Margin NaN%
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
低品質：会計処理を調査してください
株式希薄化
新株を発行しており、所有権を希薄化している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 53 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder & Independent Director | 79 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | 40 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 58 |
| Mr. Eric Pauwels | Chief Business Officer | 63 |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive VP & Chief Medical Officer | 57 |
| Ms. Christine Utter CPA | Senior VP, Chief Accounting Officer & Head of People Services | 46 |
| Ms. Linda Montella Carter | Senior VP & Chief Information Officer | - |
| Ms. Ellen Cavaleri | Head of Investor Relations | - |
| Mr. Mark Elliott Boulding J.D. | Executive VP & Chief Legal Officer | 64 |
監査リスク
3
取締役会リスク
3
報酬リスク
4
株主権利リスク
7
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for PTCT, sourced from Markets Gazette.
- 3/3/2026POSITIVEInvestment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Investor confidence in PTC Therapeutics (PTCT) appears to be on the rise, following a recent SEC filing that disclosed a significant purchase of 41,000 shares by an investment manager. This strategic move suggests a positive outlook on the future of the company, which specializes in developing therapies for rare diseases. The increased stake by an institutional player can be interpreted as a bullish signal, indicating that the market might be underestimating the potential of PTC Therapeutics' portfolio of commercial products and investigational candidates. Investors should closely monitor the stock's performance, as such an endorsement often precedes positive price movements, reflecting stronger conviction in the company's business model and long-term growth prospects within the biopharmaceutical sector.
via Markets Gazette